The most useful way to choose a probiotic is to start with a specific goal, find a strain that has been studied for that goal, and confirm the product delivers that strain at a studied dose through the end of its shelf life. Big CFU numbers and long ingredient lists matter far less.
Key takeaways
- Probiotic effects are strain-specific. A benefit shown for Lacticaseibacillus rhamnosus GG does not transfer to another L. rhamnosus strain or to “lactobacillus” in general.
- The strongest evidence is for preventing antibiotic-associated diarrhea in children and C. difficile infection in people at higher baseline risk. Evidence for IBS, immunity, and general “gut health” is weaker or mixed.
- A good label names genus, species, and strain for each organism and states live counts (CFU) guaranteed through the expiration date.
- More CFU is not automatically better. Studied doses range from about 100 million to hundreds of billions per day depending on the strain and condition.
- People who are immunocompromised, critically ill, or have a central line, and parents of preterm infants, should not use probiotics without medical guidance.
Start with the reason you want one
Probiotic marketing describes a vague destination: balance, wellness, a happier gut. The research does not work that way. Trials test a defined organism, at a defined dose, for a defined outcome, in a defined group of people. Reasonably well-studied goals include:
- Lowering the chance of diarrhea during a course of antibiotics.
- Reducing the risk of Clostridioides difficile infection during antibiotic treatment, usually in a hospital or after a prior infection.
- Easing irritable bowel syndrome (IBS) symptoms such as pain and bloating.
Goals such as “boosting immunity,” “supporting mood,” or “improving skin” have been studied, but the National Center for Complementary and Integrative Health describes most of that evidence as promising at best and often inconclusive. If your goal falls in that group, read our guide on how to evaluate supplement claims against the research before spending money.
Step 1: Learn to read the strain, not just the name
A probiotic organism is identified by genus, species, and strain designation. The NIH Office of Dietary Supplements uses Lacticaseibacillus rhamnosus GG as its example: Lacticaseibacillus is the genus, rhamnosus the species, and GG the strain, nicknamed LGG. (You may still see Lactobacillus rhamnosus GG; the genus was renamed in 2020 and many labels have not caught up.)
The strain is what connects a product to a clinical trial. Two strains of the same species can behave differently in the body, which is why the NIH fact sheet states that clinical recommendations should be strain-specific. A label that lists only “Lactobacillus acidophilus” or, worse, “proprietary probiotic blend” gives you no way to check whether the organism inside has been studied for anything.
The International Scientific Association for Probiotics and Prebiotics (ISAPP) makes the same point in its guide to decoding a probiotic label, which draws on 2002 FAO/WHO guidelines calling for genus, species, and strain designation for every organism in a product. ISAPP also cites a regional survey in which only 35% of probiotic supplements could be linked to a demonstrated health benefit based on strain and dose.
What to do with multi-strain products
Multi-strain products are not inherently better or worse, but they are harder to evaluate. ISAPP notes that a total CFU count for a blend says nothing about how much of each strain you get, and that strain ratios can shift considerably by the expiration date. Prefer products that state the count per strain, or that match a specific combination used in a trial.

Step 2: Match the strain and dose to the evidence for your goal
The table summarizes where the evidence stands for the most common reasons people buy probiotics, drawn from the NIH, NCCIH, Cochrane reviews, and the American Gastroenterological Association (AGA) guideline.
| Goal | Strength of evidence | Strains and doses studied | What guidelines say |
|---|---|---|---|
| Preventing antibiotic-associated diarrhea in children | Moderate-certainty evidence from a 2019 Cochrane review of 33 trials | L. rhamnosus (GG) and S. boulardii at 5 to 40 billion CFU/day | Cochrane authors describe these as the most appropriate options; ESPGHAN suggests at least 5 billion CFU/day for at-risk children |
| Preventing antibiotic-associated diarrhea in adults | Meta-analyses show roughly halved risk in adults under 65; no demonstrated benefit at 65 and older | S. boulardii; LGG (benefit less clear in adults) | Start within two days of the first antibiotic dose |
| Preventing C. difficile infection during antibiotics | Moderate certainty; benefit concentrated in people whose baseline risk is above 5% | S. boulardii or specific 2-, 3-, and 4-strain combinations | AGA 2020: conditional recommendation, low-quality evidence |
| Irritable bowel syndrome | Low-quality trials; possible modest benefit; no agreed strain | Various; WGO cites B. longum 35624 at 100 million CFU/day among others | AGA 2020: use only within a clinical trial |
| Ulcerative colitis or Crohn’s disease | Insufficient | Not established | AGA 2020: use only within a clinical trial |
| Acute diarrhea in children (emergency setting) | Moderate-certainty evidence of no benefit in two large North American trials | LGG tested and found ineffective | AGA 2020: suggests against use |
Antibiotic-associated diarrhea
This is the clearest use case. The NIH fact sheet reports that up to 30% of people who take antibiotics develop diarrhea. In a pooled analysis of 12 trials (1,499 participants), LGG reduced the rate from 22.4% to 12.3%, with the benefit significant in children but not adults. For Saccharomyces boulardii, a yeast rather than a bacterium, 21 trials (4,780 participants) showed risk falling from 17.4% to 8.2% in adults and from 20.9% to 8.8% in children. Starting within two days of the first antibiotic dose worked better than starting later, and benefit was seen in adults aged 18 to 64 but not in those 65 and older.
The 2019 Cochrane review in children (33 studies, 6,352 participants) found that 8% of children on a probiotic developed diarrhea versus 19% on placebo or no treatment; in trials using 5 billion CFU or more per day, the gap widened to 8% versus 23%. The reviewers rated the evidence moderate in certainty and named L. rhamnosus and S. boulardii at 5 to 40 billion CFU per day as the most appropriate choices.
C. difficile prevention
The 2025 Cochrane update pooled 31 trials with 8,672 participants and found C. difficile-associated diarrhea in 1.5% of people taking probiotics versus 4.0% of controls. The absolute benefit was small overall (about one case prevented for every 65 people treated) but considerably larger in trials where baseline risk exceeded 5%, where rates were 3.1% versus 11.6%. In lower-risk groups there was no clear difference. The AGA 2020 guideline accordingly makes a conditional suggestion for S. boulardii or specific multi-strain combinations in adults and children on antibiotics, while grading the evidence as low quality.
IBS, inflammatory bowel disease, and general digestive complaints
Here the picture is much weaker. The NIH summarizes 23 IBS trials with 2,575 patients showing a 21% reduction in the chance of persistent symptoms, but describes the study quality as low. The AGA found insufficient evidence to recommend probiotics for IBS, Crohn’s disease, or ulcerative colitis, and its guideline announcement suggested that patients taking probiotics for those conditions consider stopping, given the cost and the lack of evidence of benefit or safety. For the definitions behind these distinctions, see our explainer on prebiotics, probiotics, and postbiotics.
Step 3: Check the CFU number and when it applies
CFU stands for colony-forming units, a count of live, culturable organisms. The NIH notes that many supplements contain 1 to 10 billion CFU per dose, some contain 50 billion or more, and higher counts are not necessarily more effective. The World Gastroenterology Organisation states that it is not possible to give a general probiotic dose, because the dose that worked in a trial depends on the strain and product. Its examples range from 100 million CFU per day for one Bifidobacterium strain in IBS to 300 to 450 billion CFU three times daily for a different product.
Two label details matter more than the raw number.
When the count is guaranteed. Live cells die during storage. The NIH advises looking for a CFU figure stated through the end of shelf life rather than at the time of manufacture, and ISAPP calls an “at time of manufacture” count inadequate. A label that says “20 billion CFU at manufacture” may deliver a fraction of that by the time you open it.
Whether CFU appears at all. Under U.S. regulations, live microbial ingredients must be declared by weight on the Supplement Facts panel, and weight includes dead cells. In September 2018 the FDA issued draft guidance allowing manufacturers to add CFU counts alongside the required weight. A product that lists only milligrams of “probiotic blend” is not telling you how many live organisms you are getting. See also how to read a Supplement Facts label.
Step 4: Consider form, storage, and the expiration date
Probiotics come as capsules, powders, chewables, gummies, and drops. The form matters less than whether the organisms survive in it. Some are naturally hardy; S. boulardii is a yeast, and a 2020 review in Current Microbiology notes that its viability is not affected by antibiotics. Others are sensitive to heat and moisture.
- Storage instructions. FAO/WHO guidelines list storage conditions among the required label elements. A product labeled for refrigeration that sat on a warm shelf has probably lost potency.
- Expiration date. The end-of-shelf-life CFU guarantee is only meaningful if you use the product before that date.
- Fermented foods. ISAPP’s position is that foods with undefined cultures should be described as containing “live, active cultures,” not as probiotics, because the organisms and amounts are unknown.
Step 5: Look for independent testing and avoid the red flags
NCCIH reports that some probiotic products have been found to contain microorganisms not listed on the label, some potentially harmful. Because probiotic supplements do not go through FDA premarket review, a third-party verification seal is one of the few external checks available. Our guide to third-party testing programs explains what USP, NSF, and similar certifications verify: identity, purity, and label accuracy, not whether the strain works for your goal.
Signs a product deserves skepticism:
- No strain designations, or a “proprietary blend” with a single total CFU.
- CFU stated “at time of manufacture,” or no CFU at all.
- Disease claims such as “treats IBS.” NCCIH notes supplement labels may describe effects on body structure or function but cannot claim to treat or reduce the risk of disease without FDA authorization.
- Marketing that references “clinical studies” without naming the strain that was studied.
Who should not choose a probiotic on their own
For healthy adults, the NIH and NCCIH describe side effects as uncommon and usually mild, typically gas or bloating. The 2019 Cochrane pediatric review recorded adverse events in 4% of children on probiotics versus 6% on placebo, none judged serious.
The risk profile is different for certain groups. The NIH fact sheet documents bacteremia and fungemia, mostly in severely ill or immunocompromised patients, including at least 60 reports of fungal bloodstream infection linked to Saccharomyces probiotics since 1966, often in intensive-care patients with central lines. The WGO guideline advises restricting use in people with compromised immunity or serious underlying disease to strains with proven safety in those populations. In 2023 the FDA warned that probiotics given to preterm infants have caused invasive, sometimes fatal infections, reporting one infant death and more than two dozen other adverse events.
Key considerations before you buy
Choosing a probiotic is less about finding the “best” product and more about finding one that lines up with evidence for your goal. For preventing antibiotic-associated diarrhea, that means an LGG or S. boulardii product at a dose in the studied range, started early in the antibiotic course. For C. difficile prevention, it means recognizing that the benefit is concentrated in people at elevated risk and discussing the choice with the prescribing clinician. For IBS or general gut health, it means accepting that current guidelines do not support routine use and that any product you try is an experiment with a modest chance of success.
Whatever the goal, insist on a label that names the strain, states live counts through the expiration date, and carries a third-party seal if one is available. Axoria Reviews writes these guides from published research and official guidance rather than hands-on testing; you can read how we work in our editorial policy, and find more evidence-based guides in our Probiotics & Gut Health section.
Frequently asked questions
Is a higher CFU count always better?
No. The NIH states that higher CFU counts are not necessarily more effective, and the WGO notes that effective doses vary from 100 million to hundreds of billions per day depending on the strain. The right number is the one used in trials for your specific strain and goal, guaranteed through the expiration date.
Should I take a probiotic at the same time as my antibiotic?
The NIH fact sheet reports that starting a probiotic within two days of the first antibiotic dose was more effective than starting later. Some manufacturers suggest separating the two by a few hours so the antibiotic does not kill the probiotic bacteria, though S. boulardii, a yeast, is unaffected by antibacterial drugs. Ask your pharmacist about timing for your specific product.
Do probiotics need to be refrigerated?
It depends on the strain and formulation. Some products are shelf-stable; others lose potency quickly at room temperature. Follow the storage instructions on the label, which FAO/WHO guidelines list as a required element, and use the product before its expiration date so the end-of-shelf-life CFU guarantee applies.
Can I get the same benefit from yogurt or kimchi?
Fermented foods can contain live microorganisms, but usually in undefined types and amounts, and some are heat-treated after fermentation. ISAPP recommends describing such foods as having “live, active cultures” rather than calling them probiotics. They are not a substitute for a specific strain at a specific dose when you have a specific goal, but they can be part of a healthy diet.
How long should I take a probiotic before deciding whether it works?
For antibiotic-associated diarrhea, the probiotic is taken only for the course of antibiotics, sometimes a little longer. For symptom-based goals such as IBS, the NIH cites trials lasting 8 to 10 weeks. If you notice no change after a trial of that length, there is little reason to continue, and persistent symptoms warrant a clinical evaluation rather than a different brand.
Are probiotics safe for older adults?
Healthy older adults generally tolerate probiotics well, but the evidence for benefit is weaker. Reviews cited by both the NIH and NCCIH found no demonstrated reduction in antibiotic-associated diarrhea in people aged 65 and older. Older adults with serious illness, weakened immunity, or a central line fall into the higher-risk group and should ask a clinician first.
What does a third-party seal on a probiotic actually confirm?
Programs such as USP and NSF verify that a product contains what the label says, in the amounts listed, without harmful contaminants, and was made under good manufacturing practices. They do not evaluate whether the strain has been shown to help with any condition. Use the seal as a quality check and the strain and dose as the evidence check.
Sources
- Probiotics: Fact Sheet for Health Professionals — NIH Office of Dietary Supplements.
- Probiotics: What You Need To Know — National Center for Complementary and Integrative Health, 2019.
- AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders (Su et al., Gastroenterology 2020;159:697–705) — Guideline Central summary.
- AGA does not recommend the use of probiotics for most digestive conditions — American Gastroenterological Association news release via EurekAlert!, 2020.
- Probiotics for the prevention of pediatric antibiotic-associated diarrhea — Cochrane Database of Systematic Reviews, 2019.
- Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children — Cochrane Database of Systematic Reviews, 2025.
- Decoding a Probiotic Product Label — International Scientific Association for Probiotics and Prebiotics, 2022 (updated 2025).
- WGO Global Guidelines: Probiotics and Prebiotics — World Gastroenterology Organisation, 2023.
- FDA Issues Draft Guidance on the Labeling of Dietary Supplements Containing Live Microbials — U.S. Food and Drug Administration, 2018.
- Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases — Current Microbiology, 2020.